These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32722897)

  • 21. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
    Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
    Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
    HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
    Paton NI; Kityo C; Hoppe A; Reid A; Kambugu A; Lugemwa A; van Oosterhout JJ; Kiconco M; Siika A; Mwebaze R; Abwola M; Abongomera G; Mweemba A; Alima H; Atwongyeire D; Nyirenda R; Boles J; Thompson J; Tumukunde D; Chidziva E; Mambule I; Arribas JR; Easterbrook PJ; Hakim J; Walker AS; Mugyenyi P;
    N Engl J Med; 2014 Jul; 371(3):234-47. PubMed ID: 25014688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
    Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
    Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation.
    Panayidou K; Davies MA; Anderegg N; Egger M;
    J Int AIDS Soc; 2018 Nov; 21(11):e25200. PubMed ID: 30614622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
    Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Yeni P; Strohmaier KM; Rodgers AJ; Barnard RJ; Nguyen BY; Teppler H;
    Antivir Ther; 2015; 20(3):307-15. PubMed ID: 25350973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lamivudine monotherapy as a holding regimen for HIV-positive children.
    Patten G; Bernheimer J; Fairlie L; Rabie H; Sawry S; Technau K; Eley B; Davies MA;
    PLoS One; 2018; 13(10):e0205455. PubMed ID: 30308013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrase inhibitors in children and adolescents: clinical use and resistance.
    Torres-Fernandez D; Jiménez de Ory S; Fortuny C; Sainz T; Falcón D; Bernal E; Jiménez MC; Vilasaró MN; Epalza C; Navarro M; Ramos JT; Holguín Á; Prieto L;
    J Antimicrob Chemother; 2022 Sep; 77(10):2784-2792. PubMed ID: 35971971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
    Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS;
    Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.
    Perry CM
    Paediatr Drugs; 2014 Feb; 16(1):91-100. PubMed ID: 24277175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.
    Massanella M; Ouchi D; Marfil S; Llibre JM; Puertas MC; Buzón MJ; Richman DD; Orna E; Stevenson M; Gatell JM; Domingo P; Negredo E; Martinez-Picado J; Clotet B; Blanco J
    PLoS One; 2014; 9(12):e114142. PubMed ID: 25462535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
    Wittkop L; Breilh D; Da Silva D; Duffau P; Mercié P; Raymond I; Anies G; Fleury H; Saux MC; Dabis F; Fagard C; Thiébaut R; Masquelier B; Pellegrin I;
    J Antimicrob Chemother; 2009 Jun; 63(6):1251-5. PubMed ID: 19336453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.
    Capetti A; Landonio S; Meraviglia P; Di Biagio A; Lo Caputo S; Sterrantino G; Ammassari A; Menzaghi B; Franzetti M; De Socio GV; Pellicanò G; Mazzotta E; Soria A; Meschiari M; Trezzi M; Sasset L; Celesia BM; Zucchi P; Melzi S; Ricci E; Rizzardini G
    PLoS One; 2012; 7(7):e39222. PubMed ID: 22808029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
    Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Strohmaier KM; Wan H; Barnard RJ; Nguyen BY; Teppler H;
    Lancet Infect Dis; 2013 Jul; 13(7):587-96. PubMed ID: 23664333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium.
    Desmonde S; Neilan AM; Musick B; Patten G; Chokephaibulkit K; Edmonds A; Duda SN; Malateste K; Wools-Kaloustian K; Ciaranello AL; Davies MA; Leroy V;
    J Int AIDS Soc; 2020 Oct; 23(10):e25617. PubMed ID: 33034417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.